$DYAI News

Dyadic's Applied Biosolutions Unit Collaborates With Scripps Research To Evaluate Monoclonal Antibody And Vaccine Candidates Targeting Hantaviruses, Including Andes Virus

Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript

Dyadic International Inc (NASDAQ:DYAI) Q1 Report Beats Revenue Expectations but EPS Miss Triggers 28% After-Market Selloff

Transcript: Dyadic International Q1 2026 Earnings Conference Call

Dyadic International Q1 EPS $(0.05) Misses $(0.04) Estimate, Sales $1.111M Beat $900.000K Estimate

Dyadic International Gets Nasdaq Warning Over Listing Rules, Faces Delisting Risk

Dyadic International shares are trading lower after the company reported worse-than-expected Q4 financial results.

Dyadic International shares are trading lower after the company reported worse-than-expected Q4 financial results.

Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript

Dyadic International Inc (NASDAQ:DYAI) Reports Q4 2025 Earnings Miss, Stock Dips

Dyadic International Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $565.526K Miss $1.343M Estimate

Dyadic Applied BioSolutions Enters Into Original Equipment Manufacturer Distribution Agreement With Integrated Biotherapeutics To Expand Protein Product Reach

Dyadic And Fermbox Bio Commercially Launch Animal-Origin-Free Recombinant DNase I Under Expanded Partnership

Dyadic Applied BioSolutions And Inzymes Announced Planned 2026 Commercialization Of Recombinant Non-animal Bovine Chymosin, Key Enzyme Used In Cheese Production And Dairy Processing

Dyadic Applied Biosolutions Announces Commercial Launch Of AlbuFree DX, rHA Product Produced Using Dyadic's Proprietary Filamentous Fungal Expression Technology

DYAI: Layers of Commercialization Agreements

Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

Dyadic Applied BioSolutions Expands Collaboration With Fermbox Bio To Manufacture And Commercialize Animal-Free Proteins And Enzymes

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

Dyadic Applied Biosolutions Announced A Commercial Agreement With Opes Diagnostics To Support The Commercial Launch Of Dyadic's Recombinant Human Transferrin, Bovine Transferrin, Human FGF, And Bovine FGF Products For Use In Serum-free Cell Culture Media Applications